The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Latest updates on maintenance therapy in myeloma
Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, talks on maintenance strategies for patients with myeloma. Prof. Ludwig highlights the use of lenalidomide as the standard maintenance treatment, commenting on overall survival benefits, as well as outlining the use of carfilzomib and daratumumab. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Prof. Heinz Ludwig, MD, has received research funding from Amgen and Takeda; has been a member of a speakers bureau with Celgene, Janssen, Bristol Myers, Sanofi and Amgen; and has participated in advisory boards for Janssen, Bristol Myers, Sanofi, Amgen and Seattle Genetics.
